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Mutations in ZFHX1B, encoding Smad-interacting protein 1 (SIP1), have been recently reported to cause a form
of Hirschsprung disease (HSCR). Patients with ZFHX1B deficiency typically show mental retardation, delayed
motor development, epilepsy, microcephaly, distinct facial features, and/or congenital heart disease, in addition to
the cardinal form of HSCR. To investigate the breadth of clinical variation, we studied DNA samples from six
patients with clinical profiles quite similar to those described elsewhere for ZFHX1B deficiency, except that they
did not have HSCR. The results showed the previously reported R695X mutation to be present in three cases, with
three novel mutations—a 2-bp insertion (760insCA resulting in 254fs262X), a single-base deletion (270delG re-
sulting in 91fs107X), and a 2-bp deletion (2178delTT resulting in 727fs754X)—newly identified in the other three.
All mutations occurred in one allele and were de novo events. These results demonstrate that ZFHX1B deficiency
is an autosomal dominant complex developmental disorder and that individuals with functional null mutations
present with mental retardation, delayed motor development, epilepsy, and a wide spectrum of clinically hetero-
geneous features suggestive of neurocristopathies at the cephalic, cardiac, and vagal levels.
Introduction
Hirschsprung disease (HSCR, or aganglionic megaco-
lon [MIM 142623]) is the most common (1/5,000 live
births) congenital malformation caused by defective de-
velopment of embryonic neural crest cells at the vagal
level. The patients show severe vomiting, abdominal dis-
tention, and constipation, because of the lack of sub-
mucosal and myenteric ganglion cells along variable
lengths of the gastrointestinal tract, leading to intestinal
obstruction after birth. HSCR is genetically heteroge-
neous, and six disease-causing genes have been recently
identified: RET, encoding the RET proto-oncogene (Ed-
ery et al. 1994; Romeo et al. 1994); EDNRB, encoding
the endothelin B receptor (Puffenberger et al. 1994);
GDNF, encoding glial cell line–derived neurotrophic fac-
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tor (Angrist et al. 1996; Salomon et al. 1996); EDN3,
encoding endothelin 3 (Edery et al. 1996; Hofstra et al.
1996); Sox 10 (Pingault et al. 1998), and ECE-1, en-
coding endothelin-converting enzyme 1 (Hofstra et al.
1999). In spite of the discovery of this range of candidate
genes for HSCR, there are some associated diseases with
unknown genetic etiology.
Goldberg and Shprintzen (1981) first reported sib-
lings with an HSCR-associated disease (MIM 235730)
who presented with microcephaly, mental retardation,
hypertelorism, submucous cleft palate, and short stat-
ure. Reports of patients with overlapping collections of
these abnormalities in addition to HSCR have been re-
viewed in the literature (Fryer 1998; Mowat et al.
1998). Although they all exhibited HSCR, mental re-
tardation, microcephaly, and mild facial dysmorphol-
ogy, there is genetic and clinical heterogeneity among
the patients. The presence of clinical features such as
cleft palate, ptosis, and iris coloboma in some siblings
suggests autosomal recessive disease (Goldberg and
Shprintzen 1981; Hurst et al. 1988; Kumasaka and
Clarren 1988; Yomo et al. 1991; Fryer 1998; Brooks et
al. 1999), whereas other isolated patients with epilepsy
or congenital heart disease are likely to have contiguous
gene syndromes or dominant mutations (Hurst et al.
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Figure 1 Schematic representation of the structural organization of SIP1 and of the positions of the identified mutations. Three functional
domains (SBD, HD, and N- and C-ZF) and six identified mutations are given, with patient numbers.
1988; Halal and Morel 1990; Tanaka et al. 1993; Lurie
et al. 1994; Mowat et al. 1998). Recently, we reported
that mutations in ZFHX1B (MIM 605802; GenBank
accession number AB 056507), encoding Smad-inter-
acting protein 1 (SIP1), are a cause of the dominant
form of this disease (Wakamatsu et al. 2001).
Zfx1b (GenBank accession number AF 033116), re-
cently isolated from the mouse embryo through use of
the yeast two-hybrid system as a Smad1-interacting pro-
tein, named “Sip1,” is a new member of the dEF1/Zfh-
1 family of two-handed zinc-finger/homeodomain pro-
teins. It contains a Smad-binding domain (SBD), a
homeobox-like domain (HD), and two separated clus-
ters of zinc fingers (ZF) at the amino (N) and carboxy
(C) terminals (Verschueren et al. 1999). Each ZF cluster
binds independently, as a DNA-binding transcriptional
repressor, to the promoter regions of candidate target
genes containing one CACCT and one CACCTG or its
inverse sequence (Remacle et al. 1999; Postigo andDean
2000). Zfx1b has also been shown to interact with re-
ceptor-mediated activated full-length Smads in vitro and
is likely to be involved in the Smads-mediated signaling
cascade (Verschueren et al. 1999). ZFXH1B spans ∼70
kb, consists of 10 exons and 9 introns, and encodes
human SIP1. SIP1 consists of 1,214 amino acids (aa)
and shows 97% similarity to the mouse form (Sip1) at
the amino acid level, with exactly the same functional
domains: SBD (437–487 aa), HD (651–700 aa), and ZF
at the N and C terminals (213–304 aa and 1001–1076
aa, respectively) (fig. 1).
Because patients who have HSCR with ZFHX1B de-
ficiency have complex developmental disorders caused
by the disturbance of embryonic neural and neural-crest
development at the cephalic, cardiac, and vagal levels
(Wakamatsu et al. 2001), we speculated that they might
demonstrate a great variety of clinical features. We
therefore studied DNA samples from patients who had
clinical features quite similar to those reported for
ZFHX1B deficiency but did not have HSCR or con-
genital heart disease, and we identified mutations in six
subjects.
Subjects and Methods
Subjects
Eleven patients (1–11) in our center were included in
the present study; mutations of ZFHX1Bwere identified
in 10 of them. All patients demonstrated severe mental
retardation and delayed motor development, nine of
whom (patients 1–9) had epilepsy with a variety of clin-
ical presentations suggestive of neural crest impairment.
The results of mutation analysis of ZFHX1B in five pa-
tients (1–5) who had HSCR with short-segment agan-
glionosis have been described elsewhere (Wakamatsu et
al. 2001). In brief, patient 1 has a complete deletion of
ZFHX1B at a de novo t(2;13)(q22;q22) translocation
site on chromosome 2. Brain magnetic resonance im-
aging (MRI) revealedmoderate cerebral atrophywithout
agenesis of the corpus callosum. At age 6 years, she still
cannot stand without support. The other four patients
(2–5) also showed delayed motor functions, and they
began to walk without support at ages 3.5–8 years. Pa-
tients 2, 4, and 5 have nonsense or frameshift mutations
of ZFHX1B (fig. 1), and the cases in three patients (1,
2, and 5) are also complicated by congenital heart dis-
ease (patent ductus arteriosus [PDA]). A brain MRI of
patient 2 revealed agenesis of the corpus callosum.
Patient 6 is a 26-year-old male. He was born at 42
wk gestation, weighing 3,570 g. At age 1 year 2 mo, he
developed epilepsy, and bilateral diffuse 2–4-Hz slow
wave bursts and spikes were evident on electroenceph-
alograms (EEG); seizures could be well controlled with
anticonvulsants. He was admitted to our hospital at age
1180 Am. J. Hum. Genet. 69:1178–1185, 2001
Figure 2 Facial features of patients. Patients 6, 7, 8, and 11, at age 6, 7, 18, and 1 year(s), respectively. They demonstrate hypertelorism
(in all cases), prognathism (in all cases), a low nasal root (in the cases of patients 6, 7, and 11), absence of the internal part of the eyebrows
(in all cases), and strabismus (in the case of patient 11). Patients 6 and 7 underwent surgical correction of strabismus at age 3 years.
1 year 3 mo and was found to have microcephaly (head
circumference 45.3 cm, 2 SD below the mean) and dis-
tinct facial features (hypertelorism, external strabismus,
prognathism, and a low nasal root). He showed delayed
motor development, beginning to walk at age 6 years.
His mental development is also severely delayed, and he
has limited speech. He has had severe constipation from
birth; he has never developed ileus but still needs med-
ication for a regular stool.
Patient 7 is a 28-year-old male. He was born at 40
wk gestation, weighing 3,950 g (height 55.0 cm). He
was found to have hypertelorism and microcephaly
(head circumference 33.0 cm, 2 SD below the mean)
soon after birth. At age 6 mo, he developed epilepsy. He
showed delayed motor milestones, developing neck con-
trol at age 5 mo and walking without support at age 4
years. He also has severe mental retardation with little
linguistic ability.
Patient 8 is a 23-year-old male. He was born at 40
wk gestation, weighing 3,410 g (height 50.0 cm). He
was also found to have hypertelorism and microcephaly
(head circumference 33.0 cm, 2 SD below the mean)
soon after birth. He had a very limited appetite in his
first few years of life and developed epilepsy at age 2
years. He started to walk without support at age 2 years
6 mo. He is severely mentally impaired and can speak
only a few words (“mama,” “papa”). Patients 7 and 8
also had moderate constipation until age ∼10 years but
do not need medication now. Although patients 6, 7,
and 8 have constipation, rectal biopsies have never been
taken because until now there has been no consideration
of the possibility of HSCR.
Patient 9 is a 25-year-old male. He was born at 39
wk gestation weighing 3,260 g (height 48.0 cm), and he
had hypertelorism and microcephaly (head circumfer-
ence 33.0 cm, 2 SD below the mean). He developed
epilepsy at age 1 year. He showed delayed motor de-
velopment, with neck control developing at age 8 mo
and walking without support at age 2 years. He is se-
verely mentally retarded, with only a few words of
speech.
Patient 10 is a 4-year-old female. She was born at 36
wk gestation weighing 2,690 g (height 46.5 cm), with
microcephaly (head circumference 30.5 cm, 2 SD below
the mean). She showed delayed psychomotormilestones;
neck control was obtained at age 4 mo, she was able to
sit down by herself at age 1 year 8 mo, and she cannot
walk without support. She is active and shows curiosity
but speaks only a few words. Epilepsy has so far not
been evident. She shows distinct facial features, such as
hypertelorism, prognathism, and a low nasal root.
Patient 11 is a 1.5-year-old male. He was born at 38
wk gestation weighing 2,960 g (height 47.0 cm), with
microcephaly (head circumference 32.0 cm, 2 SD below
the mean). Neck control was obtained at age 8 mo. He
cannot sit down without support and can speak no
words at present. He has mild constipation, and his stool
is usually hard. His facial appearance is clearly indicative
of an abnormality, showing hypertelorism, external stra-
bismus, prognathism, and a low nasal root (fig. 2). There
has not been any evidence of epileptic waves on EEG.
The findings of microcephaly, delayed motor milestones,
and distinct facial features stimulated us to examine
ZFHX1B in this baby.
All patients are children of nonconsanguineous par-
ents. Deafness, pigmentation defects, iris coloboma, pto-
sis, cleft lip, and cleft palate were not observed. Brain
MRI or CT studies were performed on patients 8 and
10 at ages 22 years and 3.5 years, respectively; the results
did not show remarkable abnormalities. The clinical fea-
tures of the patients with ZFHX1B deficiency—except
for patient 3, in whom we could not identify any mu-
tation—are summarized in table 1. Photographs of pa-
tients 6, 7, 8, and 11 are given in figure 2.
Table 1
Clinical Features and Mutations Detected in Patients with ZFHX1B Deficiency
Patient
Number Sex
Current Age
(years)
Birth Weight
(g) HSCRa
Mental
Retardation Epilepsy Microcephaly
Facial
Dysmorphology
Age at Onset
of Walking
Heart
Disease
ZFHX1B
Mutation
Exon
Mutated
Brain
Abnormalityb
1 F 6 3,000       PDA Deletion All Atrophy
2 F 18 3,045      3 years 6 mo PDA R549X 8 Callosal agenesis
4 M 23 2,820      8 years  R695X 8 NE
5 M 23 3,200      5 years 3 mo PDA 392fs394X 8 NE
6 M 26 3,570 *     6 years  R695X 8 NE
7 M 28 3,950 *     4 years  R695X 8 NE
8 M 23 3,410 *     2 years 6 mo  R695X 8 Normal
9 M 25 3,260      2 years  254fs262X 6 NE
10 F 4 2,690        91fs107X 3 Normal
11 M 1.5 2,960 *       727fs754X 8 NE
NOTE.— p presence of clinical sign;  p absence of clinical sign.
a * p shows constipation.
b NE p not examined.
Table 2
Primer Sequences Used for ZFHX1B Analyses
ANALYSIS AND
PRIMER NAME EXON
PRIMER SEQUENCE (5′r3′)
ANNEALING
TEMPERATURE
(C)
PCR
FRAGMENT
LENGTH
(bp)Forward Reverse
PCR direct sequencing:
SIP-E1S/1A 1 GGAAGGGAGGGAGGTGGAAT AGGATGGAGGACGAGCACACC 58 535
SIP-E2S/2A 2 TGGTTGCTAGATCGAGCCTG GGTGCCTGACGCTCACTTTG 58 364
SIP-E3S/3A 3 GGGTGGCTGATGTTTCTCAAC GCGATCTGCTAGGTGGAACAG 58 395
SIP-E4S/4A 4 GCATGCTTAGTATAGTAAGCCT TCATTTGAATTCTCAACGACTG 58 521
SIP-E5S/6A 5, 6 AGAAGGCCCGGAAACAACAT ATATCGTTTCTCTAAGGGGTTA 58 1,209
SIP-E7S/7A 7 TTTTCTTTGTTCCTCCTGCAC TTTTTCATGGGTAGGTCTCA 58 523
SIP-E8.1S/8.1A 8 AATGTAGAGGTACCCCATTGTG CTCAGGTTGAGAGCATGGAT 58 700
SIP-E8.2S/8.2A 8 AAAAATGGACTGCAAGGCTG GTGGCTATAATACTTTTGGG 58 1,077
SIP-E8.3S/8.3A 8 CTTCTGAGGAGCTCCAGGCT CATAATCAAAATAATTGCCACCTC 58 526
SIP-E9S/9A 9 GCACAAAGAGAAGCCACTGTA GCCATCTGACTGTCCCTTTG 58 494
SIP-E10S/10A 10 TAGTGGAAAGAGACTTCATGCA TGAACAGCTTAACACAGCAGTG 58 723
Restriction enzyme
analysis:
SIP-E8R1S/1A 8 CTAATATTCCGCCTGTCGGT TTTTCATGAGGCTGCAGGAC 60 340
SIP-E8R2S/2A 8 ATGAAGAGATCAAGGCGGTC CGCTTTGAGGTGGAAGAGCT 58 888
SIP-E8R3S/3A 8 ACCCATACAAGGACCACATG TTTGAGTACTGGTAGACTaTgCa 56 157
a Mismatch primer (Tra, Trg).
PCR Amplification and DNA Sequencing
Genomic DNA was isolated from peripheral blood,
according to standard protocols. The primer pairs used
for the amplification of each exon, exon/intron bound-
ary, and part of the associated introns of ZFHX1B are
listed in table 2. Genomic DNA (100–200 ng) from each
patient and unaffected control subject was amplified by
AmpliTaq Gold (Applied Biosystems, exons 3–10) or a
GC-RICH PCR system (Roche Molecular Biochemicals,
exons 1 and 2) in a total volume of 40 ml containing
0.4 mg of each primer at the indicated annealing tem-
perature. PCR products were run on 1% agarose gels,
were purified with QIAEX II (QIAGEN), and were se-
quenced directly by methods slightly modified from
those for Sequenase Version 2.0 (United States Biochem-
ical Co.), as described elsewhere (Yamada et al. 1992).
RFLP Analysis
To identify mutations, PCR-dependent restriction en-
zyme diagnostic tests were established.
Identification of 1645ArT (R549X).—Genomic DNA
from family members of patient 2, as well as from an
unaffected control, was amplified using specific primers
for exon 8 (SIP-8R1S/1A). The PCR products were di-
gested with HphI and were separated in 1.5% low-melt-
ing-point agarose gels (Gibco-BRL).
Identification of 2083CrT (R695X).—Since PCR-de-
pendent diagnosis is very difficult with one-step PCR
(SIP-8R3S/3A), we chose two steps. First, genomic DNA
containing exon 8 of ZFHX1B was amplified with spe-
cific primers (SIP-8R2S/2A) for 20 cycles. Then, the PCR
products were diluted 500 times with TE (10 mM Tris-
HCl, pH 7.5 and 1mM EDTA) and were reamplified
with an internal mismatch primer pair (SIP-8R3S/3A)
for 30 cycles, to detect creation of aNsiI site (ATGCAT)
in the mutant DNA (table 2). The PCR products were
digested with NsiI, were electrophoresed in 1.5% low-
melting-point agarose gels, and were stained with ethi-
dium bromide.
Expression of ZFHX1B in tissue
Multiple Tissue Northern (MTN) Blots (Clontech,
#7780-1) and Multiple Tissue Expression Arrays (Clon-
tech, #7775-1) were hybridized with 32P-labeled 4.1-kb
and 685-bp (nt 1422–2106, fromATG)ZFHX1B cDNA
probes, according to the respective user’s manuals. Fil-
ters were washed with solution 1 (2# saline sodium
citrate [SSC], 1% SDS) at 65C and with solution 2
(0.1# SSC, 0.5% SDS) at 55C, for exposure of X-ray
films (RX-U; FUJIFILM).
Results
Identification of Mutations in ZFHX1B
Ten exons, splice junctions, and parts of introns from
patients 6–11 were amplified in 11 portions by PCR,
using primers specific for ZFHX1B. By direct-sequenc-
ing analysis of PCR-amplified ZFHX1B fragments,
R695X nonsense mutations in exon 8 were identified in
three patients (6–8), a 2-bp insertion (760insCA result-
ing in 254fs262X) was identified in exon 6 of patient
9, a single-base deletion (270delG resulting in 91fs107X)
was identified in exon 3 of patient 10, and a 2-bp de-
letion (2178delTT resulting in 727fs754X) was identi-
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Figure 3 Expression patterns of ZFHX1B. A, Autoradiograph showing hybridization with a 685-bp ZFHX1B cDNA against a Multiple
Tissue Expression Array mRNA dot blot. The order and arrangement of applied samples are given in panel B. C, Autoradiographs of northern
blots hybridized with a 4.1-kb ZFHX1B full-length cDNA (containing all exons) and a 2.0-kb human b-actin cDNA as a control: lane 1, brain;
lane 2, heart; lane 3, skeletal muscle; lane 4, colon; lane 5, thymus; lane 6, spleen; lane 7, kidney; lane 8, liver; lane 9, small intestine; lane 10,
placenta; lane 11, lung; and lane 12, peripheral blood leukocytes.
fied in exon 8 of patient 11. These are summarized, with
the previously reported ZFHX1B mutations, in table 1
and figure 1.
Detection of Disease Mutations by RFLP
To determine whether the mutations we identified also
appeared in patients’ family members, we established
diagnostic tests specific to each mutation; these tests
were based on performance of restriction-enzyme cleav-
age of PCR products, either directly or by primers flank-
ing each mutation site (table 2). The assays demonstrat-
ed that patient 2, as well as four others (patients 4
and 6–8), were heterozygous for their identified muta-
tions—R549X and R695X, respectively. However, all of
their parents showed normal alleles (data not shown).
Direct-sequencing analysis for the parents of patient
5 (1173delAACA), patient 9 (760insCA), patient 10
(270delG), and patient 11 (2178delTT) also showed
them to have normal alleles (data not shown). Thus, the
ZFHX1B mutations identified in the patients were all
de novo events.
ZFHX1B Tissue Expression and Transcripts
Hybridization of a ZFHX1B-specific probe to mRNA
samples derived frommany human tissues revealed ubiq-
uitous expression, predominantly in brain (except in the
pituitary gland), with small amounts in esophagus, kid-
ney, thymus, pancreas, thyroid gland, salivary gland, and
in tumor cell lines (fig. 3A). Northern blot analysis re-
vealed one dominant ZFHX1B transcript (∼6 kb; fig.
3B).
Discussion
In the present article, we describe a mutation analysis
of ZFHX1B, encoding human SIP1, in six patients with
profound mental retardation, delayed motor develop-
ment, epilepsy, and mild facial dysmorphology, as well
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as in four previously reported patients with ZFHX1B
deficiency (Wakamatsu et al. 2001). Comparison of the
clinical presentations of the 10 patients indicates that
ZFHX1B deficiency is a complex developmental disor-
der with a wide spectrum of clinical features suggestive
of neurocristopathies at the cephalic (distinct facial fea-
tures and microcephaly), cardiac (PDA), and vagal levels
(HSCR) (table 1). RFLP studies or direct-sequencing
analysis of identified mutations of family members dem-
onstrated the ZFHX1B deficiency to be caused by de
novo mutations that cause a complete deletion (in pa-
tient 1) or null functions (in patients 2 and 4–11). Thus,
ZFHX1B deficiency is an autosomal dominant complex
developmental disorder caused by a decrease to half of
the normal amount of active SIP1 during embryogenesis.
In the present study, we found a nonsense mutation,
R695X, in 4 of 10 independent patients, generating a
CrT transition at the CpG doublet as a de novo event.
Data from studies on the molecular evolution of various
vertebrate DNA sequences suggest that the CpG doublet
is a favored target for mutations. Many mutant se-
quences feature CpG-to-TpG or CpG-to-CpA substi-
tutions (Cooper and Youssoufian 1988), and this site is
likely to be a hot spot for ZFHX1B mutations. Fur-
thermore, RFLP analysis to identify R695X in the pre-
sent studymight be considered a useful tool for newborn
screening for ZFHX1B deficiency.
Although all of our patients have mental retardation,
delayed motor development, microcephaly, and distinct
facial features in common, eight have epilepsy (not ev-
ident in patients 10 and 11), only three have PDA, and
four have HSCR. The constipation observed in four
patients (6, 7, 8, and 11) is suggestive of a partial defect
in ganglion cells of the gastrointestinal tract. However,
intensive studies, including rectal biopsies, have not yet
been performed (table 1). This finding that the pene-
trance of possible neurocristopathies at the cardiac and
vagal levels is variable suggests that the associated phe-
notypes may be less sensitive to a decrease in the normal
amount of SIP1. The fact that four patients (4 and 6–8)
with the R695X mutation showed different clinical
presentations, with and without HSCR, further indi-
cates that unknown factors, possibly environmental in
nature and occurring during embryonic development,
may exert important influences (table 1). Other disease-
causing genes may also be present, because we did not
find any ZFHX1B mutations in patient 3. The identi-
fication of 10 patients in our center who have ZFHX1B
deficiency and show a wide spectrum of clinical varia-
tion, however, suggests that this is one common can-
didate gene for syndromic mental retardation associated
with delayed motor development, epilepsy, and neuro-
cristopathies. Patients having missense mutations—for
example, in functional domains (SBD or ZF) of
ZFHX1B—have yet to be identified, but it would be of
interest to clarify what clinical features theywould have.
Very recently, Comijn et al. (2001) clearly demon-
strated that E-cadherin is one target gene of SIP1 in
epithelial tumor cell lines. SIP1 has an important role
in the invasion of these tumors, by downregulating the
transcription of E-cadherin. In the present study, we
provide evidence that SIP1 is essential for normal de-
velopment of brain and, most likely, for development
of the neural crest.
Although ZFHX1B was here found to be expressed
ubiquitously, albeit with very different levels in different
tissues (fig. 3), strictly regulated precise expression
would be essential for normal embryonic neural and
neural crest development at the correct stages of em-
bryogenesis. Identification and analysis of target genes
of SIP1, including E-cadherin, especially in neural and
neural crest cells, during embryonic development should
provide insights into the molecular mechanisms under-
lying mental retardation, epilepsy, and a variety of
neurocristopathies.
Note.—During the review of this article, Cacheux et
al. (2001) reported the ZFHX1B mutations in patients
with a syndromic HSCR.
Acknowledgments
We are grateful to the patients and their families for agreeing
to participate in this study. This work was supported by a
Grant-in-Aid for Scientific Research on Priority Areas
(C)–Advanced Brain Science Project, from the Ministry of Ed-
ucation, Culture, Sports, Science, and Technology, Japan (to
N.W. and K.K.) and by a grant from the Tsubaki Memorial
Neuroscience Research Foundation (to N.W.).
Electronic-Database Information
Accession numbers and URLs for data in this article are as
follows:
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/index.html
(for ZFHX1B mRNA [accession number AB 056507] and
Zfx1b [Mus musculus] [accession number AF 033116])
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for HSCR [MIM 142623], HSCR
with microcephaly, mental retardation, and distinct facial
features [MIM 235730], and ZFHX1B, encoding SIP1
[MIM 605802])
References
Angrist M, Bolk S, Halushka M, Lapchak PA, Chakravarti A
(1996) Germline mutations in glial cell line-derived neuro-
trophic factor (GDNF) and RET in a Hirschsprung disease
patient. Nat Genet 14:341–344
Brooks AS, Breuning MH, Osinga J, vd Smagt JJ, Catsman
CE, Buys CHCM, Meijers C, Hofstra RMW (1999) A con-
Yamada et al.: Nonsense and Frameshift Mutations in ZFHX1B 1185
sanguineous family with Hirschsprung disease, microceph-
aly, and mental retardation (Goldberg-Shprintzen syn-
drome). J Med Genet 36:485–489
Cacheux V, Dastot-Le Moal F, Ka¨a¨ria¨inen H, Bondurand N,
Rintala R, Boissier B, Wilson M, Mowat D, Goossens M
(2001) Loss-of-function mutations in SIP1 Smad interacting
protein 1 result in a syndromic Hirschsprung disease. Hum
Mol Genet 10:1503–1510
Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven
L, Bruyneel E, Mareel M, Huylebroeck D, van Roy F (2001)
The two-handed E box binding zinc finger protein SIP1
downregulates E-cadherin and induces invasion. Mol Cell
7:1267–1278
Cooper DN, Youssoufian H (1988) The CpG dinucleotide and
human genetic disease. Hum Genet 78:151–155
Edery P, Attie´ T, Amiel J, Pelet A, Eng C,Hofstra RMW,Martelli
H, Bidaud C, Munnich A, Lyonnet S (1996) Mutation of the
endothelin-3 gene in the Waardenburg-Hirschsprung disease
(Shah-Waardenburg syndrome). Nat Genet 12:442–444
Edery P, Lyonnet S, Mulligan LM, Pelet A, Dow E, Abel L,
Holder S, Nihoul-Fe´ke´te´ C, Ponder BAJ, Munnich A (1994)
Mutations of the RET proto-oncogene in Hirschsprung’s
disease. Nature 367:378–380
Fryer AE (1998) Goldberg-Shprintzen syndrome: report of a
new family and review of the literature. Clin Dysmorphol
7:97–101
Goldberg RB, Shprintzen RJ (1981) Hirschsprung megacolon
and cleft palate in two sibs. J Craniofac Genet Dev Biol 1:
185–189
Halal F,Morel J (1990) The syndrome ofHirschsprung disease,
microcephaly, unusual face, and mental retardation. Am J
Med Genet 37:106–108
Hofstra RMW, Osinga J, Tan-Sindhunata G, Wu Y, Kamsteeg
EJ, Stulp RP, van Ravenswaaij-Arts C, Majoor-Krakauer D,
Angrist M, Chakravarti A, Meijers C, Buys CHCM (1996)
A homozygous mutation in the endothelin-3 gene associated
with a combined Waardenburg type 2 and Hirschsprung
phenotype (Shah-Waardenburg syndrome). Nat Genet 12:
445–447
Hofstra RMW, Valdenaire O, Arch E, Osinga J, KroesH, Lo¨ffler
BM, Hamosh A, Meijers C, Buys CHCM (1999) A loss-of-
function mutation in the endothelin-converting enzyme 1
(ECE-1) associated with Hirschsprung disease, cardiac de-
fects, and autonomic dysfunction. Am J Hum Genet 64:
304–308
Hurst JA, Markiewicz M, Kumar D, Brett EM (1988) Un-
known syndrome: Hirschsprung’s disease, microcephaly,
and iris coloboma: a new syndrome of defective neuronal
migration. J Med Genet 25:494–497
Kumasaka K, Clarren SK (1988) Familial patterns of central
nervous system dysfunction, growth deficiency, facial clefts
and congenital megacolon: a specific disorder? Am J Med
Genet 31:465–466
Lurie IW, Supovitz KR, Rosenblum-Vos LS, Wulfsberg EA
(1994) Phenotypic variability of del(2) (q22-q23): report of
a case with a review of the literature. Genet Couns 5:11–14
Mowat DR, Croaker GDH, Cass DT, Kerr BA, Chaitow J, Ade`s
LC, Chia NL, Wilson MJ (1998) Hirschsprung disease, mi-
crocephaly, mental retardation, and characteristic facial fea-
tures: delineation of a new syndrome and identification of a
locus at chromosome 2q22-q23. J Med Genet 35:617–623
Pingault V, Bondurand N, Kuhlbrodt K, Goerich DE, Pre´hu
MO, Puliti A, Herbarth B, Hermans-Borgmeyer I, Legius E,
Matthijs G, Amiel J, Lyonnet S, Ceccherini I, Romeo G,
Smith JC, Read AP, Wegner M, Goossens M (1998) SOX10
mutations in patients with Waardenburg-Hirschsprung dis-
ease. Nat Genet 18:171–173
Postigo AA, Dean DC (2000) Differential expression and func-
tion of members of the zfh-1 family of zinc finger/homeo-
domain repressors. Proc Natl Acad Sci USA 97:6391–6396
Puffenberger EG, Hosoda K, Washington SS, Nakao K, deWit
D, Yanagisawa M, Chakravarti A (1994) A missense mu-
tation of the endothelin-B receptor gene in multigenic
Hirschsprung’s disease. Cell 79:1257–1266
Remacle JE, Kraft H, Lerchner W, Wuytens G, Collart C, Ver-
schueren K, Smith JC, Huylebroeck D (1999) New mode of
DNA binding of multi-zinc finger transcription factors: dEF1
family members bind with two hands to two target sites.
EMBO J 18:5073–5084
Romeo G, Ronchetto P, Luo Y, Barone V, Seri M, Ceccherini
I, Pasini B, Bocciardi R, Lerone M, Ka¨a¨ria¨inen H, Martuc-
ciello G (1994) Point mutations affecting the tyrosine kinase
domain of the RET proto-oncogene in Hirschsprung’s dis-
ease. Nature 367:377–378
Salomon R, Attie´ T, Pelet A, Bidaud C, Eng C, Amiel J, Sar-
nacki S, Goulet O, Ricour C, Nihoul-Fe´ke´te´ C, Munnich A,
Lyonnet S (1996) Germline mutations of the RET ligand
GDNF are not sufficient to cause Hirschsprung disease. Nat
Genet 14:345–347
Tanaka H, Ito J, Cho K, Mikawa M (1993) Hirschsprung
disease, unusual face, mental retardation, epilepsy, and con-
genital heart disease: Goldberg-Shprintzen syndrome. Pe-
diatr Neurol 9:479–481
Verschueren K, Remacle JE, Collart C, Kraft H, Baker BS,
Tylzanowski P, Nelles L, Wuytens G, Su MT, Bodmer R,
Smith JC, Huylebroeck D (1999) SIP1, a novel zinc finger/
homeodomain repressor, interacts with Smad proteins and
binds to 5′-CACCT sequences in candidate target genes. J
Biol Chem 274:20489–20498
Wakamatsu N, Yamada Y, Yamada K, Ono T, Nomura N,
Taniguchi H, Kitoh H, Mutoh N, Yamanaka T, Mushiake
K, Kato K, Sonta S, Nagaya M (2001) Mutations in SIP1,
encoding Smad interacting protein-1, cause a form of
Hirschsprung disease. Nat Genet 27:369–370
Yamada Y, Goto H, Suzumori K, Adachi R, Ogasawara N
(1992) Molecular analysis of five independent Japanese mu-
tant genes responsible for hypoxanthine quanine phosphor-
ibosyltransferase (HPRT) deficiency. HumGenet 90:379–384
Yomo A, Taira T, Kondo I (1991) Goldberg-Shprintzen syn-
drome: Hirschsprung disease, hypotonia, and ptosis in sibs.
Am J Med Genet 41:188–191
